Related Experiment Video
Updated: Jan 24, 2026

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
Published on: April 13, 2021
Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients
Busaya Kulabusaya1,2, Somratai Vadcharavivad3, Yingyos Avihingsanon4
1Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, 10330, Thailand.
Abstract:
Background The effects of mycophenolic acid exposure in the early period after transplantation on clinical outcomes have been reported; however, mycophenolic acid exposure in the early period after transplantation in Asian kidney transplant recipients who receive 1.5 g/d mycophenolate mofetil has never been investigated. Objective To determine mycophenolic acid exposure on day 3 post-transplantation in kidney transplant recipiens who receive 1.5 g/d mycophenolate mofetil. The effects of the reduced renal function on mycophenolic acid area under the concentration-time curve (AUC) and the achievement of the target AUC on the incidence of biopsy proven acute rejection during the first month post-transplantation were also evaluated. Setting A university hospital Method Blood samples and 24-h urine were collected on day 3 post-transplantation. Main outcome measures The mycophenolic acid AUC was calculated by linear trapezoidal rule and compared with the target of 45 mg*h/L. Results Of 42 Thai kidney transplant recipiens, the mean mycophenolic acid AUC of 45.1 mg*h/L (SD 14.7) was comparable to the AUC target (P = 0.962). Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017). Proportions of overall biopsy proven acute rejection among patients with mycophenolic acid AUC of < 45 and ≥ 45 mg*h/L were comparable (20.0% and 23.5%, respectively; P = 1.000). Conclusions After the starting dosage of 1.5 g/d mycophenolate mofetil, the mean mycophenolic acid AUC on day 3 post-kidney transplantation is comparable with the target of 45 mg*h/L. Severely reduced renal function significantly influences mycophenolic acid exposure.
Insights
Mycophenolic acid exposure in Asian kidney transplant recipients on day 3 post-transplantation with mycophenolate mofetil (1.5 g/d) was comparable to the target AUC. Reduced renal function significantly impacts mycophenolic acid exposure.
Area of Science:
- Pharmacokinetics and clinical outcomes in transplantation medicine.
- Immunosuppressive drug monitoring in organ recipients.
Background:
- Early post-transplant mycophenolic acid (MPA) exposure effects are known, but not specifically in Asian kidney transplant recipients using 1.5 g/d mycophenolate mofetil (MMF).
- Investigating MPA exposure is crucial for optimizing immunosuppression and preventing rejection in this population.
Purpose of the Study:
- To determine MPA exposure (AUC) on day 3 post-transplantation in Asian kidney transplant recipients receiving 1.5 g/d MMF.
- To evaluate the impact of reduced renal function on MPA AUC and its relation to biopsy-proven acute rejection (BPAR).
Main Methods:
- Blood and 24-h urine samples collected on day 3 post-kidney transplantation.
- MPA area under the concentration-time curve (AUC) calculated using the linear trapezoidal rule.
- MPA AUC compared to a target of 45 mg*h/L; effects of renal function (urine output, CrCl) and BPAR incidence assessed.
Main Results:
- Mean MPA AUC (45.1 mg*h/L) was comparable to the target of 45 mg*h/L in 42 Thai kidney transplant recipients (P=0.962).
- Significantly lower MPA AUC observed in patients with urine output <2400 mL (35.3) vs. ≥2400 mL (47.4) (P=0.002).
- MPA AUC was lower in patients with CrCl <25 mL/min (38.0) vs. ≥25 mL/min (49.2) (P=0.017).
- BPAR incidence was similar between patients with MPA AUC <45 and ≥45 mg*h/L (20.0% vs. 23.5%, P=1.000).
Conclusions:
- A starting dose of 1.5 g/d MMF achieves a comparable mean MPA AUC on day 3 post-kidney transplantation.
- Severely reduced renal function significantly influences MPA exposure in kidney transplant recipients.
- MPA AUC on day 3 did not correlate with acute rejection rates in this cohort.
Related Concept Videos
Dosage Regimens: Partial Pharmacokinetic Parameters
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Dosage Regimen: Multiple Oral Dosage
Kidney Transplant III: Nursing Management
Dosage Compensation
In addition to sexual development, the X chromosome has genes involved in autosomal functions such as brain development and the immune system. Therefore, males and females with distinct numbers of X chromosomes will...

